Aslan Fred sold $422K of ARTV

Aslan Fred (Chief Executive Officer) sold 61,696 shares of Artiva Biotherapeutics, Inc. (ARTV) at $6.84 ($0.42M total) on 2026-10-05.

Original reporting
SEC EDGAR · Aslan Fred
Published Oct 6, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Bearish
medium confidence
Mentioned
$ARTV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBearishLow
01

Why it matters

The disclosed sale is modest in size and may cause slight short‑term pressure on the stock, but broader market impact is limited.

02

Market read

Primary insider sale filing; low to moderate relevance for traders monitoring insider activity.

03

What to watch

Potential upcoming clinical data releases that may offset any negative sentiment from the sale.

Relevance 4/10Novelty 4/10Timing: today

Background

SEC Form 4 filing discloses an insider transaction by Artiva Biotherapeutics' CEO.

Company-level read

Ticker impact

$ARTVBearishMedium confidence
Context

CEO Aslan Fred sold 61,696 shares for $421,828, reducing his stake; a primary Form 4 filing.

Expected impact

likely slight downward pressure as the market prices the insider sell

Evidence & confidence

Insider sales, especially by a CEO, are often interpreted as a lack of confidence, but the amount ($422K) is modest for a mid‑cap biotech, so impact is limited.

Market effects

Minimal; biotech sector unlikely to move on a single small insider sale.

None; the filing is company‑specific.

None

Counterpoint

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • Artiva Biotherapeutics, Inc.

    Biotech firm listed on Nasdaq under ticker ARTV.

  • Aslan Fred

    Chief Executive Officer of Artiva Biotherapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.